Werewolf Therapeutics, Inc.

NasdaqGS:HOWL

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

Location

United States

Market Cap

USD 55.64 M

Share Price

USD 1.24

Avg Daily Volume

393,277

Change (1 day)

2.48%

Change (1 year)

-57.09%

Change (YTD)

-16.22%

Werewolf Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2025

Werewolf Therapeutics, Inc. EBT Margin is NA for the Trailing 12 Months (TTM) ending March 31, 2025. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Werewolf Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was -256.33%, a 6.01% change year over year.
Werewolf Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -241.79%.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBT Margin	Operating Income Margin	Gross Profit Margin	EBIT Margin

NasdaqGS: HOWL

Werewolf Therapeutics, Inc.

CEO	Dr. Daniel J. Hicklin Ph.D.
IPO Date	April 30, 2021
Location	United States
Headquarters	1030 Massachusetts Avenue
Employees	46
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials

Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.